Northwind Pharmaceuticals

New drugs approved for 2014-A Recap of What We’ve Seen This Year

New-drugs-approved-for-2014-A-Recap-of-What-We’ve-Seen-This-YearAs we look back on 2014, it’s been a big year when it comes to newly approved medications. The FDA has been busy, with a long list of both generic and brand name pharmaceuticals getting their stamp of approval. Let’s talk highlights.

  • Cardiology and Vascular Diseases – Zontivity:  For the reduction of thrombotic cardiovascular events.
  • Family Medicine – Arnuity Ellipta: For the treatment of asthma.
  • Gastroenterology – Cyramza: For the treatment of gastric cancer.
  • Genetic Disease – Alprolix:  For the treatment of hemophilia B.
  • Immunology – Triumeq: For the treatment of HIV-1.
  • Musculoskeletal – Vimizim: For the treatment of Mucopolysaccharidosis type IVA.
  • Nephrology – Harvoni: For the treatment of hepatitis C.
  • Neurology – Belsomra: For the treatment of insomnia.
  • Nutrition and Weight Loss – Contrave: For chronic weight management.

To see a full list of all 2014 FDA approved medications click here.

Available pharmaceuticals change from year to year, with more being added all the time. When you partner with Northwind Pharmaceuticals, you have access to top industry information on the best medications to prescribe to your patients. When drugs become available, we’ll track them down and provide you with a competitive price supported by our responsive customer service. Contact us today to see how our solutions can lead to greater success in 2015.

Schedule a free claims analysis now.

Let’s Talk now

Podcast: Northwind’s Member Focused Approach

Phillip Berry | Sep 25th, 2024
Click here to listen to Katherine Lurke, PharmD and Steve Zetzl, PharmD discuss Northwind’s member focused approach to pharmacy benefit management. Unlike traditional PBM models like you are used to hearing about, Northwind’s PSA (Phamacy Administration Services) prioritizes continuous patient engagement. Steve and Katherine break down how their team works to ensure that once medications are in … more »

continue reading

We’re All in the Business of Healthcare

Phillip Berry | Aug 14th, 2024
Employers and unions have begun to realize that they are very much in the business of healthcare and that they are the “payer.” The move toward self-funding continues to build momentum as costs increase and employers discover that the healthcare universe revolves around a few massive payers. American healthcare has become a $4.5 trillion galaxy … more »

continue reading

The PBM Conflagration Marks the Beginning of Healthcare’s Center-of-Gravity Shift

Phillip Berry | Jul 31st, 2024
Waiting for my turn to present at recent health system executive conference, I noticed that presentations before mine spent a significant amount of time lamenting “payers” and “reimbursements.” Strategies and solutions to address these challenges centered on cutting costs, pooling resources to increase negotiating leverage, lobbying, and aligning with larger health systems to bolster positioning. … more »

continue reading